Short-Term Apixaban for Documented Left Atrial Appendage Thrombus in High-Risk Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion

Ding, Wern Yew; Lip, Gregory Y H; Fairbairn, Timothy; Binukrishnan, Sukumaran; Khalatbari, Afshin; Velavan, Periaswamy; Gupta, Dhiraj

Published in:
TH Open

DOI (link to publication from Publisher):
10.1055/s-0040-1718585

Creative Commons License
CC BY 4.0

Publication date:
2020

Document Version
Publisher's PDF, also known as Version of record

Link to publication from Aalborg University

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.
Short-Term Apixaban for Documented Left Atrial Appendage Thrombus in High-Risk Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion

Wern Yew Ding1, Gregory Y.H. Lip1,2, Timothy Fairbairn3, Sukumaran Binukrishnan3, Afshin Khalatbari3, Periaswamy Velavan3, Dhiraj Gupta1

1 Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
2 Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark
3 Department of Cardiology, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom


Address for correspondence Dhiraj Gupta, MD, Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool, L14 3PE, United Kingdom (e-mail: Dhiraj.Gupta@lhch.nhs.uk).

Stroke prevention with left atrial appendage (LAA) occlusion is an important alternative treatment for high-risk atrial fibrillation (AF) patients with contraindications to oral anticoagulation (OAC).1,2 The presence of LAA thrombus detected on preprocedural imaging usually precludes implantation of the endocardial device because of a prohibitively high periprocedural embolic risk.3 Although successful resolution of LAA thrombus with OAC has been described, all previous reports are in patients without contraindications to OAC.4–6 Furthermore, long-term data in these patients are lacking. We hypothesized that short-term OAC with apixaban could safely facilitate resolution of LAA thrombi even in a high-risk population, thereby allowing safe LAA occluder device implantation, with good outcomes over the long term.

This was a retrospective cohort study of 83 patients who underwent work-up for LAA occlusion at our center between January 2015 and December 2017. LAA thrombi were documented in 11 (13.3%) patients (mean age: 76.9 [± 6.9] years; 7 males) on preprocedural imaging (9 on transesophageal echocardiography and 2 on cardiac computed tomographic angiography) (Table 1). All patients with LAA thrombi had permanent AF, with median CHA2DS2-VASc and HAS-BLED scores of 4 (interquartile range [IQR]: 3–5) and 2 (IQR: 2–3), respectively. Contraindications to lifelong OAC in this cohort were prior intracranial hemorrhage in six patients (two on warfarin, one on dabigatran, one on heparin, and two while not on anticoagulation), prior gastrointestinal hemorrhage requiring emergency hospital admission and blood transfusion in three patients (two on warfarin and one while not on anticoagulation), severe unexplained anemia on dabigatran in one patient, and failed OAC in one patient. At the time of imaging, none of the patients were receiving OAC, and four (36.4%) patients were on a single antiplatelet agent. There were no significant differences between patients who had documented LAA thrombus compared with those without in terms of age (p = 0.80), sex category (p = 0.74), AF type (p = 0.11), comorbidities (hypertension [p = 0.50], diabetes mellitus [p = 0.31], and prior stroke or transient ischemic attack [p = 0.47]), and CHA2DS2-VASc score (p = 0.69).

The potential risks of surgical thrombectomy and ligation were felt to outweigh the benefits. Hence, following detection of LAA thrombi, off-label dose-adjusted apixaban (2.5 mg twice daily for three patients and 5 mg twice daily for eight patients) was prescribed for each patient. The choice of anticoagulation was based on evidence of potential favorable characteristics of apixaban compared with other OAC in terms of efficacy and safety profile.7 Repeat imaging in the form of transesophageal echocardiography, or cardiac computed tomographic angiography was scheduled at 6- to 8-week intervals. Complete resolution of LAA thrombus was observed in 10 (90.9%) patients after apixaban treatment for a median of 94 days (IQR: 44–126 days). During treatment with apixaban, one patient (who received a dose of 5 mg twice daily) had a severe gastrointestinal bleed requiring blood transfusion, and one patient suffered an ischemic stroke with subsequent full recovery. There was no significant difference in the risk of bleeding according to apixaban dosage (p = 0.73). One patient (patient 8, Table 1) had persistent LAA thrombus on repeated imaging, and a
performing LAA occlusion without delay in patients with a high-risk profile of coagulopathy might help in minimizing the exposure to OAC in this high-risk cohort by reducing the risk of thromboembolism.

Baseline. It is also worth noting that we adopted a strategy of patient-centered decision was ultimately taken for continued apixaban therapy despite prior major intracranial bleed while on warfarin. In this patient, no bleeding complications were observed over a follow-up period of 25 weeks.

The 10 patients with thrombus resolution underwent successful LAA occlusion with no peri procedural complications. Apixaban was replaced by dual-antiplatelet therapy with aspirin and clopidogrel for 6 weeks postprocedure followed by single (or no) antiplatelet therapy. The decision to discontinue long-term antiplatelet therapy in three patients was based on an individualized approach after accounting for their high bleeding risk. All patients underwent cardiac imaging with transesophageal echocardiography at 6 to 8 weeks postprocedure; no device-related thrombus was observed in any patient. Across a median follow-up of 2.5 years (IQR: 0.6–3.3 years), one patient suffered a transient ischemic attack and another had an episode of severe epistaxis despite not being on antiplatelet or OAC therapy at the time. During this same period, four (40%) patients died.

Given the low number of patients, our study was underpowered and should therefore be interpreted with caution. Furthermore, the incidence of LAA thrombus in our study may not reflect those of the general AF population as many of our high-risk patients were not on anticoagulation therapy at baseline. It is also worth noting that we adopted a strategy of minimizing the exposure to OAC in this high-risk cohort by performing LAA occlusion without delay in patients with a confirmed resolution of LAA thrombi.

Our experience suggests that short-term treatment with apixaban may be effective and safe for aiding the resolution of documented LAA thrombus in high-risk patients who are ineligible for lifelong OAC therapy. This strategy allows the LAA occlusion procedure to be undertaken safely, thereby potentially reducing the long-term risk of thromboembolism.

**Table 1** Characteristics of patients with left atrial appendage thrombus

<table>
<thead>
<tr>
<th>Patients</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>Age: 82 y; eGFR: 42; CHA2DS2-VASc: 3; HAS-BLED: 2; recurrent GI bleed on warfarin; OGD revealed gastric angiodysplasia; CKD; COPD; angina</td>
</tr>
<tr>
<td>Patient 2</td>
<td>Age: 76 y; eGFR: 74; CHA2DS2-VASc: 5; HAS-BLED: 2; recurrent GI bleed on warfarin; no source identified on OGD and colonoscopy</td>
</tr>
<tr>
<td>Patient 3</td>
<td>Age: 75 y; eGFR: 90; CHA2DS2-VASc: 4; HAS-BLED: 3; massive GI bleed while off anticoagulation; OGD identified variceal source, which was treated with banding; nonalcoholic liver cirrhosis; old inferior MI; mild LV dysfunction; hypothyroidism</td>
</tr>
<tr>
<td>Patient 4</td>
<td>Age: 78 y; eGFR: 53; CHA2DS2-VASc: 5; HAS-BLED: 2; ICH on heparin for newly diagnosed atrial fibrillation; prior ischemic stroke; CKD; HTN; hypothyroidism</td>
</tr>
<tr>
<td>Patient 5</td>
<td>Age: 81 y; eGFR: 64; CHA2DS2-VASc: 3; HAS-BLED: 3; ICH on warfarin (subtherapeutic international normalized ratio); meningoia; epilepsy; HTN; prior pneumothorax</td>
</tr>
<tr>
<td>Patient 6</td>
<td>Age: 80 y; eGFR: 48; CHA2DS2-VASc: 4; HAS-BLED: 3; ICH on dabigatran; CKD; epilepsy; uncontrolled HTN; treated breast cancer</td>
</tr>
<tr>
<td>Patient 7</td>
<td>Age: 68 y; eGFR: 47; CHA2DS2-VASc: 6; HAS-BLED: 2; ICH while off anticoagulation; cerebral amyloid angiopathy; prior stroke; old MI; severe LV dysfunction; CKD; HTN</td>
</tr>
<tr>
<td>Patient 8</td>
<td>Age: 88 y; eGFR: 67; CHA2DS2-VASc: 3; HAS-BLED: 2; large ICH on warfarin; HTN</td>
</tr>
<tr>
<td>Patient 9</td>
<td>Age: 67 y; eGFR: 75; CHA2DS2-VASc: 5; HAS-BLED: 3; ICH while off anticoagulation; recurrent stroke and transient ischemic attack; prior pulmonary embolism and deep venous thrombosis; seizures; left ventricular hypertrophy</td>
</tr>
<tr>
<td>Patient 10</td>
<td>Age: 83 y; eGFR: 44; CHA2DS2-VASc: 4; HAS-BLED: 2; severe anemia of unknown origin while on dabigatran; CKD; left bundle branch block; HTN</td>
</tr>
<tr>
<td>Patient 11</td>
<td>Age: 68 y; eGFR: 67; CHA2DS2-VASc: 5; HAS-BLED: 3; ischemic stroke on apixaban; cerebral amyloid angiopathy; prior embolic stroke; polycythemia; COPD; alcohol excess; HTN</td>
</tr>
</tbody>
</table>

**Abbreviations:** CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; HTN, hypertension; ICH, intracranial hemorrhage; LV, left ventricular; MI, myocardial infarction; OGD, esophagogastroduodenoscopy.

---

Conflict of Interest

G.Y.H.L. is a consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseau, and Daiichi-Sankyo and speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fee is directly received personally. D.G. is a speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Medtronic, Biosense Webster, and Boston Scientific and proctor for Abbott. Research grants from Medtronic, Biosense Webster, and Boston Scientific were received. The funders had no role in the submitted paper. D.G. reports personal fee from Abbott. The other authors report no conflict of interests.

**References**

6 Lip GYH, Hammerstingl C, Marin F, et al; X-TRA study and CLOT-AF registry investigators. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J 2016;178:126–134